STOCK TITAN
  1. Home
  2. News
  3. SYBX

Synlogic Inc - SYBX STOCK NEWS

Welcome to our dedicated news page for Synlogic (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synlogic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synlogic's position in the market.

News
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Rhea-AI Summary
Synlogic, Inc. has closed its underwritten public offering, raising approximately $21.0 million. The offering consisted of 7,394,363 shares of common stock and accompanying warrants. The offering price per share was $2.84, with the warrants having an exercise price of $3.408 per share. The proceeds from the offering, along with existing cash and cash equivalents, are expected to fund operations until the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
offering
-
News
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
Rhea-AI Summary
Synlogic, Inc. announces pricing of public offering, expecting $21.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.08%
Tags
offering
-
News
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
Rhea-AI Summary
Synlogic, Inc. announces positive results from its Synpheny-1 Phase 2 study of labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU). The study shows dose-dependent reductions in plasma phenylalanine (Phe). Urgency to complete Synpheny-3 trial and advance potential new treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1032.62%
Tags
clinical trial
News
Synlogic Announces Reverse Stock Split
Rhea-AI Summary
Synlogic, Inc. will implement a 1-for-15 Reverse Stock Split to maintain its listing on Nasdaq. The split will reduce the number of outstanding shares from 69.0 million to 4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags
none
-
News
Synlogic to Participate in Chardan’s Genetic Medicines Conference
Rhea-AI Summary
Synlogic, Inc. to participate in Chardan's Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
-
News
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
Rhea-AI Summary
Synlogic CEO honored as PharmaVoice 100 winner
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.81%
Tags
none
News
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Synlogic, Inc. reported financial results for Q2 2023 and provided an update on its pipeline programs. The company initiated a pivotal Phase 3 trial for labafenogene marselecobac as a potential treatment for PKU and received Fast Track designation from the FDA. They also announced the acceptance of the international non-proprietary name for the drug candidate. Synlogic had cash and cash equivalents of $46.3 million as of June 30, 2023, and expects to have sufficient cash to fund operations into the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
earnings
-
News
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
Rhea-AI Summary
Synlogic, Inc. has received Fast Track designation from the FDA for labafenogene marselecobac, a potential treatment for phenylketonuria (PKU). The drug has also received Rare Disease Designation and Orphan Drug Designation from the FDA, as well as orphan designation from the EMA. Synlogic is pleased with the regulatory designations, reflecting the urgent need for new treatment options for PKU patients. The Fast Track designation will enable the company to expedite the development and review process, with benefits including frequent meetings with the FDA, rolling basis approval, and eligibility for priority review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
clinical trial
-
News
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.9%
Tags
none
News
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.75%
Tags
none
Stock SYBX logo
Synlogic Inc

Nasdaq:SYBX

SYBX Rankings

#5087 Ranked by Market Cap
#101 Ranked by Stock Gains
N/A Ranked by Dividends

SYBX Stock Data

20.62M
2.90M
10.29%
70.46%
0.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SYBX

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre